Marilena Vrana: Insights from the Alpha-1 Alliance Event on Advancing Plasma Access in the EU
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Honoured to take part in the Alpha-1 Europe Alliance asbl event, hosted by MEP Olivier Chastel at the European Parliament.
Powerful patient stories and healthcare professionals insights on Alpha-1 Antitrypsin Deficiency highlighted a broader imperative: ensuring sustainable and equitable access to plasma-derived medicines for all patients across Europe.
From PPTA Europe perspective, one message is clear: achieving EU resilience and moving towards self-sufficiency in hashtag#plasma supply will require a truly collective effort.
Public, private and nonprofit collectors, healthcare professionals, patient communities, and policymakers all have a role to play.
This is particularly relevant in the context of implementing the EU SoHO Regulation.
Making its objectives a reality will depend on collaboration, aligned regulatory frameworks, and sustained investment, especially to scale up plasmapheresis capacity across all EU Member States.
Strengthening awareness, improving plasma collection capabilities, and coordinated action are essential steps to close the plasma supply gap and meet the real patient need.
Thank you to Flaminia Macchia for facilitating the discussion and to all panelists for this important exchange.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 12:12Mona Ranade: Insights from a Medeloop Analytics Study Evaluate Catheter-Directed Therapy in Pulmonary Embolism
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?